Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -11,336 | -4,073 | -11,405 | -9,327 | -6,017 |
| Depreciation Amortization | 28 | 14 | 44 | 29 | 18 |
| Accounts payable and accrued liabilities | -35 | 111 | 18 | 216 | -144 |
| Other Working Capital | -685 | -107 | -64 | -127 | -172 |
| Other Operating Activity | 7,377 | 1,907 | 2,445 | 2,691 | 2,095 |
| Operating Cash Flow | $-4,651 | $-2,149 | $-8,962 | $-6,518 | $-4,220 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -8 | N/A | -111 | -54 | -52 |
| Investing Cash Flow | $-8 | $N/A | $-111 | $-54 | $-52 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 11,337 | 11,337 | N/A | N/A | N/A |
| Other Financing Activity | 0 | 0 | 12,291 | 12,291 | 12,291 |
| Financing Cash Flow | $11,337 | $11,337 | $12,291 | $12,291 | $12,291 |
| Beginning Cash Position | 10,491 | 10,491 | 7,273 | 7,273 | 7,273 |
| End Cash Position | 17,169 | 19,678 | 10,491 | 12,991 | 15,292 |
| Net Cash Flow | $6,678 | $9,188 | $3,218 | $5,718 | $8,019 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,651 | -2,149 | -8,962 | -6,518 | -4,220 |
| Capital Expenditure | -8 | N/A | -111 | -54 | -52 |
| Free Cash Flow | -4,659 | -2,149 | -9,073 | -6,572 | -4,271 |